SCHEMBL25322835

SCHEMBL25322835

CC(C)(C)OC(=O)N1CCC(O)(c2ccnc(N3CCCC3)c2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 7/20 0.48
CKS1B P61024 2/20 0.44
SKP1 P63208 2/20 0.44
SKP2 Q13309 2/20 0.44
LRRK2 Q5S007 1/20 0.42
OPRD1 P41143 1/20 0.42
OPRK1 P41145 1/20 0.42
SYK P43405 1/20 0.42
CYP2D6 P10635 2/20 0.41
TSHR P16473 2/20 0.41
CYP2C19 P33261 2/20 0.41
HSD17B10 Q99714 2/20 0.41
CYP3A4 P08684 1/20 0.41
MAP4K4 O95819 1/20 0.41
POLB P06746 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
HPGD P15428 1/20 0.40
MAPK1 P28482 1/20 0.40
PDK2 Q15119 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29475514 0.83 DDB1 (0.47) GPR119CKS1BSKP1SKP2OPRD1
SCHEMBL25318673 0.83 DDB1 (0.47) GPR119CKS1BSKP1SKP2OPRD1
SCHEMBL20753895 0.83 JAK1 (0.49) GPR119OPRD1OPRK1SYKPOLB
SCHEMBL13660761 0.83 POLB (0.47) GPR119OPRD1OPRK1SYKTSHR
SCHEMBL20754002 0.81 JAK2 (0.48) GPR119OPRD1OPRK1SYKPOLB
SCHEMBL25458288 0.80 GPR119 (0.50) GPR119OPRD1OPRK1TSHRPOLB
SCHEMBL15228419 0.76 GPR119 (0.56) GPR119CKS1BSKP1SKP2LRRK2
SCHEMBL11956931 0.76 GPR119 (0.53) GPR119OPRD1OPRK1TSHRCYP2C19
SCHEMBL25262553 0.76 JAK2 (0.44) GPR119OPRD1OPRK1SYKPOLB
SCHEMBL11963375 0.75 CKS1B (0.55) GPR119CKS1BSKP1SKP2LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240043395-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING NEUROPORE THERAPIES, INC. 2024-02-08 US disclosed
EP-4217342-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING Neuropore Therapies, Inc. (US) 2023-08-02 EP disclosed
CN-116507607-A Compounds and compositions as modulators of TLR signaling 神经孔疗法股份有限公司 2023-07-28 CN disclosed
WO-2022067114-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING NEUROPORE THERAPIES, INC. (US) 2022-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240043395-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF TLR SIGNALING TLR3, TLR6, TLR4 GPR119 867/4885CKS1B 2531/4885SKP1 3548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.